Similarly, we believe that CAD patients carrying the 25 bp polymorphic deletion in MYBPC3 when triggered by severe ischemic insult to the cardiac muscle cell (in place of viral infection or other contributory factors for the development of DCM) may be more likely to develop severe LV dysfunction in comparison to CAD patients who are not carrying this mutation. This evidence concerns the gene MYBPC3 and coronary artery disorder.